^
Association details:
| Biomarker: | HER-2 underexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | SAR443216 (HER2 inhibitor, CD3 agonist, T-cell stimulant, CD28 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1825 - SAR443216, a novel trispecific T cell engager with potent T cell-dependent cytotoxicity for HER2-low tumors
Published date:
03/10/2021
Excerpt:
Finally, in a HER2-low breast cancer xenograft model, SAR443216 also exhibited significant anti-tumor activity in immuno-deficient NSG mice reconstituted with primary human T cells. Thus, SAR443216 represents a promising new drug for cancer patients with HER2-expressing tumors, including those who are currently ineligible for stand-of-care therapy.
